Dr. Reinhard von Roemeling, MD
Dr. Reinhard von Roemeling, MD is an internationally recognized medical oncologist and clinical scholar with deep knowledge and experience in oncology drug development. During his academic career, Dr. von Roemeling served as a faculty member and attending medical oncologist at the University of Minnesota, Texas University Health Sciences Center, Albany Medical College and VA Medical Center, and Fox Chase Comprehensive Cancer Center. He has extensive global experience successfully designing robust protocols and advancing clinical trials encompassing both strong clinical and research components within large portfolios. Dr. von Roemeling directed/co-directed/supported 25+ small molecules and biologics development programs, including 10 as immunotherapy/immune-modulators in combination with other drugs (PD-(L)1 checkpoint inhibitors.
Dr. von Roemeling has held executive leadership positions at several pharmaceutical companies and served as the Global Head of Research and Development at HUYA Bioscience International; Senior Vice President, Clinical Development Oncology/Global TA Head Oncology at EMD-Serono/Merck KGaA Research and Development Institute; Vice President, Clinical Development Oncology at Daiichi Sankyo Pharma Development; Vice President, Global Head – Clinical Development at Fresenius Biotech, Inc.; Vice President, Global Medical Affairs-Hematology/Oncology at Schering AG/Berlex; International Head – Therapeutic Area Oncology at Boehringer-Ingelheim Pharmaceuticals. Currently, Dr. von Roemeling is the Senior Vice President, Clinical Development of Curis, Inc.
As an eminent physician-scientist, Dr. von Roemeling has extensive global clinical development experience for oncology drugs with demonstrated success in multiple NDA- and BLA-approvals of small molecule drugs as well as large molecule biologics. His contributions include the accelerated approval of the immune-oncology drug Avelumab for multiple indications; approval of Catumaxomab (Removab™ CD-3/EpCAM bispecific, tri-functional antibody) for malignant ascites from EpCAM+ malignancies (Ovarian Cancer, Gastro-intestinal Cancers); and approval of the radioimmunoconjugate Ibritumomab Tiuxetan (Zevalin™ – yttrium / CD-20 radioimmunoconjugate for non-Hodgkin’s lymphoma) to name just a few. Dr. von Roemeling is a prolific clinical scholar having published 97 research articles.